BridgeBio Oncology Therapeutics (BBOT) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of BridgeBio Oncology Therapeutics (NASDAQ: BBOT) recently:

• 9/14/2026 – BridgeBio Oncology Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/12/2026 – BridgeBio Oncology Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/11/2026 – BridgeBio Oncology Therapeutics had its price target lowered by JPMorgan Chase & Co. from $25.00 to $23.00. They now have an “overweight” rating on the stock.
• 9/10/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Leerink Partners to $27.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Raymond James Financial, Inc. from $24.00 to $22.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Stifel Nicolaus from $23.00 to $15.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $23.00 to $20.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $25.00 price target on the stock.
• 8/14/2026 – BridgeBio Oncology Therapeutics had its price target lowered by JPMorgan Chase & Co. from $27.00 to $25.00. They now have an “overweight” rating on the stock.

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company seeks to address cancer-driving alterations that may be underserved by existing treatments, using targeted therapies designed to match the molecular characteristics of individual tumors.

Its pipeline includes BBO-8520, an investigational KRAS G12C inhibitor designed to target both active and inactive forms of the KRAS G12C protein.